APO Research
Talk to an analyst

APO RESEARCH · REPORT

DPP-4 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025191 pages

Choose your research edition.

Industry ResearchDPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global DPP-4 Inhibitors for Type 2 Diabetes Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment include Novartis, Merck, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Mitsubishi Tanabe Pharma, LG Life Sciences and Dong-A Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DPP-4 Inhibitors for Type 2 Diabetes Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DPP-4 Inhibitors for Type 2 Diabetes Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DPP-4 Inhibitors for Type 2 Diabetes Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Novartis

Merck

Eli Lilly and Company

AstraZeneca

Takeda Pharmaceutical

Sanwa Kagaku Kenkyusho

Mitsubishi Tanabe Pharma

LG Life Sciences

Dong-A Pharmaceuticals

Bristol-Myers Squibb

Boehringer Ingelheim

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Alogliptin

Linagliptin

Saxagliptin

Vildagliptin

Sitagliptin

Others

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application

Hospitals and Clinics

Offline Retail Pharmacy

E-commerce and Internet Medical Care

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DPP-4 Inhibitors for Type 2 Diabetes Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 2. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 3. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 4. DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 5. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers (M Pcs) & (2021-2026) Table 8. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers Table 9. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Sales Price (US$/K Pcs) of Manufacturers (2021-2026) Table 10. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers, Product Type & Application Table 13. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alogliptin Table 17. Major Manufacturers of Linagliptin Table 18. Major Manufacturers of Saxagliptin Table 19. Major Manufacturers of Vildagliptin Table 20. Major Manufacturers of Sitagliptin Table 21. Major Manufacturers of Others Table 22. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type 2021 VS 2025 VS 2032 (M Pcs) Table 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 25. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2026) Table 26. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2027-2032) Table 27. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type 2021 VS 2025 VS 2032 (M Pcs) Table 28. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (M Pcs) Table 29. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (M Pcs) Table 30. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2026) Table 31. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospitals and Clinics Table 33. Major Manufacturers of Offline Retail Pharmacy Table 34. Major Manufacturers of E-commerce and Internet Medical Care Table 35. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application 2021 VS 2025 VS 2032 (M Pcs) Table 36. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 37. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 38. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2026) Table 39. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2027-2032) Table 40. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application 2021 VS 2025 VS 2032 (M Pcs) Table 41. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (M Pcs) Table 42. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (M Pcs) Table 43. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2026) Table 44. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2027-2032) Table 45. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 46. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 47. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2026) Table 48. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecasted by Region (2027-2032) & (M Pcs) Table 49. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecasted Market Share by Region (2027-2032) Table 50. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 51. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 52. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 53. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 54. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 55. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 56. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 57. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 58. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 59. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 60. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 61. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 62. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2021-2026) & (US$ Million) Table 64. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2027-2032) & (US$ Million) Table 65. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2026) Table 66. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2027-2032) Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 71. Novartis Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 76. Merck Recent Development Table 77. Eli Lilly and Company Company Information Table 78. Eli Lilly and Company Business Overview Table 79. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 81. Eli Lilly and Company Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Takeda Pharmaceutical Company Information Table 88. Takeda Pharmaceutical Business Overview Table 89. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 91. Takeda Pharmaceutical Recent Development Table 92. Sanwa Kagaku Kenkyusho Company Information Table 93. Sanwa Kagaku Kenkyusho Business Overview Table 94. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 96. Sanwa Kagaku Kenkyusho Recent Development Table 97. Mitsubishi Tanabe Pharma Company Information Table 98. Mitsubishi Tanabe Pharma Business Overview Table 99. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 101. Mitsubishi Tanabe Pharma Recent Development Table 102. LG Life Sciences Company Information Table 103. LG Life Sciences Business Overview Table 104. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 106. LG Life Sciences Recent Development Table 107. Dong-A Pharmaceuticals Company Information Table 108. Dong-A Pharmaceuticals Business Overview Table 109. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 111. Dong-A Pharmaceuticals Recent Development Table 112. Bristol-Myers Squibb Company Information Table 113. Bristol-Myers Squibb Business Overview Table 114. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 116. Bristol-Myers Squibb Recent Development Table 117. Boehringer Ingelheim Company Information Table 118. Boehringer Ingelheim Business Overview Table 119. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Price (US$/K Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 121. Boehringer Ingelheim Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 125. DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Image Figure 2. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 5. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alogliptin Image Figure 9. Linagliptin Image Figure 10. Saxagliptin Image Figure 11. Vildagliptin Image Figure 12. Sitagliptin Image Figure 13. Others Image Figure 14. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 15. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032) Figure 17. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 18. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032) Figure 20. Hospitals and Clinics Image Figure 21. Offline Retail Pharmacy Image Figure 22. E-commerce and Internet Medical Care Image Figure 23. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 24. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032) Figure 26. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 27. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032) Figure 29. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 30. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032) Figure 31. U.S. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 32. Canada DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 33. Mexico DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 34. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 35. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032) Figure 36. Germany DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 37. France DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 38. U.K. DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 39. Italy DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 40. Netherlands DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 41. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 42. Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032) Figure 43. China DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 44. Japan DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 45. South Korea DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 46. Southeast Asia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 47. India DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 48. Australia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 49. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 50. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2032) Figure 51. Brazil DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 52. South Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 53. Saudi Arabia DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 54. Turkey DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 55. Argentina DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 56. UAE DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 57. Egypt DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 58. Chile DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales and Growth Rate (2021-2032) & (M Pcs) Figure 59. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Figure 62. North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Figure 64. Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 70. Manufacturing Cost Structure Figure 71. DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Saxagliptin
  • Vildagliptin
  • Sitagliptin
  • Others
Applications
  • Hospitals and Clinics
  • Offline Retail Pharmacy
  • E-commerce and Internet Medical Care
Companies covered
  • Novartis
  • Merck
  • Eli Lilly and Company
  • AstraZeneca
  • Takeda Pharmaceutical
  • Sanwa Kagaku Kenkyusho
  • Mitsubishi Tanabe Pharma
  • LG Life Sciences
  • Dong-A Pharmaceuticals
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
  1. 2.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Manufacturers
  1. 3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers, Product Type & Application
  7. 3.7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 DPP-4 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3
4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Type
  1. 4.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Type Introduction
  2. 4.1.1 Alogliptin
  3. 4.1.2 Linagliptin
  4. 4.1.3 Saxagliptin
  5. 4.1.4 Vildagliptin
  6. 4.1.5 Sitagliptin
  7. 4.1.6 Others
  8. 4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
  9. 4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  11. 4.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032)
  12. 4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type
  13. 4.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  15. 4.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032)
5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Application
  1. 5.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Application Introduction
  2. 5.1.1 Hospitals and Clinics
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 E-commerce and Internet Medical Care
  5. 5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
  6. 5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application
  10. 5.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032)
6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region
  1. 6.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region
  1. 7.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region
  2. 7.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032)
  8. 7.2.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032)
  11. 7.3.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Takeda Pharmaceutical
  26. 8.5.1 Takeda Pharmaceutical Company Information
  27. 8.5.2 Takeda Pharmaceutical Business Overview
  28. 8.5.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 8.5.5 Takeda Pharmaceutical Recent Developments
  31. 8.6 Sanwa Kagaku Kenkyusho
  32. 8.6.1 Sanwa Kagaku Kenkyusho Company Information
  33. 8.6.2 Sanwa Kagaku Kenkyusho Business Overview
  34. 8.6.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 8.6.5 Sanwa Kagaku Kenkyusho Recent Developments
  37. 8.7 Mitsubishi Tanabe Pharma
  38. 8.7.1 Mitsubishi Tanabe Pharma Company Information
  39. 8.7.2 Mitsubishi Tanabe Pharma Business Overview
  40. 8.7.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 8.7.5 Mitsubishi Tanabe Pharma Recent Developments
  43. 8.8 LG Life Sciences
  44. 8.8.1 LG Life Sciences Company Information
  45. 8.8.2 LG Life Sciences Business Overview
  46. 8.8.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 8.8.5 LG Life Sciences Recent Developments
  49. 8.9 Dong-A Pharmaceuticals
  50. 8.9.1 Dong-A Pharmaceuticals Company Information
  51. 8.9.2 Dong-A Pharmaceuticals Business Overview
  52. 8.9.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 8.9.5 Dong-A Pharmaceuticals Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 9.1.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
  6. 9.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
  9. 9.2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst